Your browser doesn't support javascript.
loading
Willingness to Use Long-acting Injectable Pre-exposure Prophylaxis Among Key Populations at a Large Hiv Prevention Clinic in Kampala, Uganda: a Cross-sectional Study.
Lukubuya, Jonathan Derrick; Katana, Elizabeth B; Baguma, Micheal; Kaguta, Andrew; Nambatya, Winnie; Kyambadde, Peter; Muwonge, Timothy R; Mujugira, Andrew; Odongpiny, Eva Agnes Laker.
Afiliación
  • Lukubuya JD; School of Pharmacy, College of Health Sciences, Makerere University.
  • Katana EB; Uganda National Institute of Public Health, Ministry of Health.
  • Baguma M; School of Pharmacy, College of Health Sciences, Makerere University.
  • Kaguta A; School of Pharmacy, College of Health Sciences, Makerere University.
  • Nambatya W; School of Pharmacy, College of Health Sciences, Makerere University.
  • Kyambadde P; Most At Risk Populations Initiative (MARPI), Mulago National Referral Hospital.
  • Muwonge TR; The Infectious Diseases Institute, College of Health Sciences, Makerere University.
  • Mujugira A; The Infectious Diseases Institute, College of Health Sciences, Makerere University.
  • Odongpiny EAL; The Infectious Diseases Institute, College of Health Sciences, Makerere University.
Res Sq ; 2024 Aug 05.
Article en En | MEDLINE | ID: mdl-39149453
ABSTRACT

Background:

Long-acting injectable (LAI)-PrEP provides better protection against HIV compared to oral PrEP, which requires taking a daily pill. Our study aimed to assess knowledge about oral and LAI-PrEP and identify factors associated with willingness to use LAI-PrEP among key populations (KP) in Uganda.

Methods:

We conducted a cross-sectional study at the Most at Risk Populations Initiative (MARPI) clinic between November and December 2021. Participants were recruited through convenience sampling and interviewed using a structured questionnaire by trained interviewers. Participants were categorised into three groups based on their oral PrEP use those who had not yet initiated PrEP, those who had discontinued oral PrEP, and those currently on oral PrEP. Modified Poisson regression analysis was performed to determine factors associated with the participant's willingness to use LAI-PrEP. Data was analysed using STATA 14 software.

Results:

Of the 234 participants, 135 (56.7%) were female, 82.5% knew about LAI-PrEP, and 67.5% were willing to use it. The mean age was 28.7 years (standard deviation [SD] 5.8). Willingness to use LAI-PrEP was less likely among divorced, widowed, or separated individuals than those in relationships (adjusted prevalence ratio [aPR] 0.65, 95% CI 0.43-0.98). Relative to current oral PrEP users, willingness to use LAI-PrEP was similar among those who discontinued oral PrEP (aPR 1.39, 95% CI 0.92-2.11) and those who had not yet initiated PrEP but were at risk for HIV (aPR 1.26, 95% CI 0.83-1.89).

Conclusions:

In this cross-sectional analysis of diverse members of key populations in Uganda, previous or non-use of oral PrEP was not associated with willingness to use LAI-PrEP relative to current users. Future studies should investigate effective methods for promoting the uptake of long-acting PrEP formulations among populations at high risk of HIV acquisition.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Res Sq Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Res Sq Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos